Eviti Connect study showed an increase in clinical uptake of practice-changing data San Antonio, TX – December 11, 2019 –...
Landmark FDA clearance of whole exome sequencing in vitro diagnostic (IVD) test reporting overall tumor mutation burden (TMB) by sequencing...
This designation reaffirms that NantHealth is a trusted leader in utilization review and is committed to quality and transformative healthcare,...
Results to be presented during the developmental immunotherapy and tumor immunobiology session at the American Society of Clinical Oncology (ASCO)...
Results to be presented during the cancer prevention, hereditary genetics and epidemiology session at the ASCO 2019 Annual Meeting CHICAGO,...
Findings to be presented at the 2019 American Society of Clinical Oncology’s Genitourinary Cancers Symposium San Francisco and Culver City,...
Findings demonstrate the need for comprehensive personalized tumor testing to deliver actionable insights and inform effective treatment plans San Francisco,...
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding...
Topics to include DNA and RNA profiling and next-generation sequencing of tumors San Antonio, TX – Dec 3, 2018 –...
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer MUNICH and CULVER CITY,...